China Medical System Wins NMPA Nod to Start Trials of Novel Oral PNH Drug CMS-D017

An announcement from China Medical System Holdings ( (HK:0867) ) is now available.

China Medical System Holdings has received approval from China’s National Medical Products Administration to begin clinical trials in healthy participants for CMS-D017, a self-developed, orally administered, small-molecule inhibitor of complement factor B intended to treat paroxysmal nocturnal hemoglobinuria (PNH). By selectively targeting the alternative complement pathway upstream and inhibiting C3 convertase formation, CMS-D017 is designed to address both intravascular and extravascular hemolysis while potentially lowering infection risk compared with existing C5 inhibitors that require intravenous or subcutaneous administration. The company expects that, once approved for marketing, CMS-D017 will significantly strengthen its nephrology franchise and create strong synergies with its existing and pipeline kidney-disease drugs, boosting its competitiveness and market position, while it accelerates preparations to launch the product following completion of clinical development.

The most recent analyst rating on (HK:0867) stock is a Hold with a HK$14.00 price target. To see the full list of analyst forecasts on China Medical System Holdings stock, see the HK:0867 Stock Forecast page.

More about China Medical System Holdings

China Medical System Holdings is a pharmaceutical group focused on developing and commercialising innovative therapies, with an emerging specialty in nephrology. Its portfolio includes the marketed chronic kidney disease drug Velphoro for hyperphosphatemia and Oxemia for renal anemia, which is under regulatory review, supported by established expert networks and market resources in China’s healthcare sector.

Average Trading Volume: 4,399,854

Technical Sentiment Signal: Buy

Current Market Cap: HK$34.01B

See more insights into 0867 stock on TipRanks’ Stock Analysis page.